- Gilead Sciences Inc GILD warned Thursday that its original HIV treatments Biktarvy and Descovy had been replaced by fake versions at some pharmacies.
- Unauthorized distributors could sell fake drugs to retailers, and then, "genuine Gilead bottles" were filled with counterfeit tablets, the company said.
- Gilead has alerted potentially impacted pharmacies and is working with the FDA, pharmacies, and legal authorities to remove problematic pills from circulation and to prevent future distribution, the company added.
- Gilead didn't disclose the number of pharmacies affected or where they are located.
- Counterfeit medicines may not have the correct amount of active ingredients or may contain impurities.
- Approved by the FDA in 2018, Biktarvy quickly became the industry's best-selling HIV med and a key growth driver for Gilead.
- In the first half of 2021, the drug brought in $3.82 billion worldwide, roughly a 16% increase over the same period last year.
- Descovy, combined with other drugs to treat HIV and used by itself as a PrEP option to prevent infection, brought in sales of $794 million in the first six months of 2021.
- Price Action: GILD shares closed down 0.75% at $68.78 on Friday.
- Photo by Mika Baumeister on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in